CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
License and milestone fees	$ 11,540	$ 18,730
Non-cash royalty revenue related to the sale of future royalties	7,190	7,613
Research and development support	383	1,478
Clinical materials revenue	702	678
Total revenues	19,815	28,499
Operating Expenses:
Research and development	44,831	32,888
General and administrative	9,995	8,119
Restructuring charge	1,731	386
Total operating expenses	56,557	41,393
Loss from operations	(36,742)	(12,894)
Investment income, net	662	115
Non-cash interest expense on liability related to the sale of future royalties and convertible senior notes	(3,046)	(3,575)
Interest expense on convertible senior notes	(24)	(1,125)
Other income, net	537	134
Net loss	$ (38,613)	$ (17,345)
Basic and diluted net loss per common share (in dollar per share)	$ (0.30)	$ (0.20)
Basic and diluted weighted average common shares outstanding (in shares)	130,619	87,160
Total comprehensive loss	$ (38,613)	$ (17,345)